Nicolas Sluis‐Cremer

4.0k citations

111 papers · 3.1k indexed · h-index 34

Co-authors: Gilda Tachedjian John W. Mellors Michael A. Parniak Dominique Arion Jessica Radzio Kelly Huber Heini W. Dirr Yohei Doi
Topics: HIV Research and Treatment (89 papers)HIV/AIDS drug development and treatment (83 papers)HIV/AIDS Research and Interventions (37 papers)
Cited by: Virology Infectious Diseases Molecular Medicine
Journals: Proceedings of the National Academy of Sciences Nucleic Acids Research Journal of Biological Chemistry
Partner nations: United States Australia Canada

In The Last Decade

Nicolas Sluis‐Cremer

107 papers receiving 3.1k citations

Peers

Countries citing papers authored by Nicolas Sluis‐Cremer

Since Specialization

Citations

This map shows the geographic impact of Nicolas Sluis‐Cremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Sluis‐Cremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Sluis‐Cremer more than expected).

Fields of papers citing papers by Nicolas Sluis‐Cremer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Sluis‐Cremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Sluis‐Cremer. The network helps show where Nicolas Sluis‐Cremer may publish in the future.

Co-authorship network of co-authors of Nicolas Sluis‐Cremer

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Sluis‐Cremer. A scholar is included among the top collaborators of Nicolas Sluis‐Cremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Sluis‐Cremer. Nicolas Sluis‐Cremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Senescence-related cytokine levels are associated with HIV-1 serostatus and persistence 2025 ·AIDS ·Yijia Li,(unknown),(unknown),(unknown),Mounia Alaoui-El-Azher,Paolo Piazza,Yue Chen,Nicolas Sluis‐Cremer,(unknown),Bernard Macatangay	2
2	Structural basis of deoxynucleotide addition by HIV-1 RT during reverse transcription 2024 ·Nature Communications ·Sandra Vergara,Xiaohong Zhou,Ulises Santiago,Mounia Alaoui-El-Azher,James F. Conway,Nicolas Sluis‐Cremer,Guillermo Calero	2
3	Mechanism by Which PF-3758309, a Pan Isoform Inhibitor of p21-Activated Kinases, Blocks Reactivation of HIV-1 Latency 2023 ·Biomolecules ·(unknown),James Boslett,Nathan A. Yates,Nicolas Sluis‐Cremer	1
4	Targeting HIV-1 Reverse Transcriptase Using a Fragment-Based Approach 2023 ·Molecules ·(unknown),(unknown),Shane Dawson,Adam Johnson,(unknown),Menachem J. Gunzburg,Catherine F. Latham,Νicholas Barlow,(unknown),Paula Ellenberg,Stephen J. Headey,Nicolas Sluis‐Cremer,David Tyssen,Joseph D. Bauman,Francesc X. Ruiz,Eddy Arnold,David K. Chalmers,Gilda Tachedjian	4
5	RING Program: The CFAR Diversity, Equity, and Inclusion Pathway Initiative 2023 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Nicolas Sluis‐Cremer,(unknown),(unknown),(unknown),Patricia Ortiz‐Bermúdez,Robert Ross,Alan D. Levine	1
6	The role of adjuvants in overcoming antibacterial resistance due to enzymatic drug modification 2022 ·RSC Medicinal Chemistry ·(unknown),(unknown),(unknown),Felcia Lai,Bryson A. Hawkins,Jonathan J. Du,Eric J. Sundberg,Nicolas Sluis‐Cremer,David E. Hibbs,Paul W. Groundwater	12
7	B Lymphocytes, but Not Dendritic Cells, Efficiently HIV-1 Trans Infect Naive CD4 ⁺ T Cells: Implications for the Viral Reservoir 2021 ·mBio ·(unknown),(unknown),Paolo Piazza,Mounia Alaoui-El-Azher,Charles R. Rinaldo,Nicolas Sluis‐Cremer,Giovanna Rappocciolo	6
8	Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1 2019 ·EBioMedicine ·Jan Kristoff,(unknown),Tatiana M. García-Bates,Chengli Shen,Nicolas Sluis‐Cremer,Phalguni Gupta,Charles R. Rinaldo,Robbie B. Mailliard	18
9	High-Level Fosfomycin Resistance in Vancomycin-Resistant Enterococcus faecium 2017 ·Emerging infectious diseases ·Yan Guo,(unknown),Christi L. McElheny,Vaughn S. Cooper,Amelia Tait‐Kamradt,Minggui Wang,Fupin Hu,Louis B. Rice,Nicolas Sluis‐Cremer,Yohei Doi	23
10	Glutathione-S-transferase FosA6 ofKlebsiella pneumoniaeorigin conferring fosfomycin resistance in ESBL-producingEscherichia coli 2016 ·Journal of Antimicrobial Chemotherapy ·Qinglan Guo,(unknown),Christi L. McElheny,Vaughn S. Cooper,Nicole Stoesser,Minggui Wang,Nicolas Sluis‐Cremer,Yohei Doi	50
11	Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells 2015 ·Current Topics in Medicinal Chemistry ·Nicolas Sluis‐Cremer	2
12	Failure of Initial Therapy With Two Nucleosides and Efavirenz Is Not Associated With Early Emergence of Mutations in the C-Terminus of HIV-1 Reverse Transcriptase 2011 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jessica H. Brehm,Christina M. Lalama,Michael D. Hughes,Richard Haubrich,Sharon A. Riddler,Nicolas Sluis‐Cremer,John W. Mellors	3
13	Synthesis and evaluation of 3′-azido-2′,3′-dideoxypurine nucleosides as inhibitors of human immunodeficiency virus 2009 ·Bioorganic & Medicinal Chemistry Letters ·Hongwang Zhang,Steven J. Coats,(unknown),Franck Amblard,Mervi Detorio,Ghazia Asif,Emilie Fromentin,Sarah Solomon,(unknown),Tony Whitaker,Nicolas Sluis‐Cremer,John W. Mellors,Raymond F. Schinazi	11
14	Silent mutations are selected in HIV-1 reverse transcriptase and affect enzymatic efficiency 2008 ·AIDS ·P. Richard Harrigan,(unknown),(unknown),Brian Wynhoven,(unknown),Viviane D. Lima,Pierre Lecocq,(unknown),Art F. Y. Poon,Nicolas Sluis‐Cremer	13
15	N348I in the Connection Domain of HIV-1 Reverse Transcriptase Confers Zidovudine and Nevirapine Resistance 2007 ·PLoS Medicine ·(unknown),(unknown),Jonathan M. Fahey,Mark Zanin,David Tyssen,Viviane D. Lima,Brian Wynhoven,Michael J. Kuiper,Nicolas Sluis‐Cremer,P. Richard Harrigan,Gilda Tachedjian	138
16	Potent Nonnucleoside Reverse Transcriptase Inhibitors Target HIV-1 Gag-Pol 2006 ·PLoS Pathogens ·Anna Figueiredo,Katie L. Moore,Johnson Mak,Nicolas Sluis‐Cremer,Marie‐Pierre de Béthune,Gilda Tachedjian	85
17	Dimerization of Human Immunodeficiency Virus Type 1 Reverse Transcriptase as an Antiviral Target 2006 ·Current Pharmaceutical Design ·Seema Srivastava,Nicolas Sluis‐Cremer,Gilda Tachedjian	24
18	Stereo‐selectivity of HIV‐1 reverse transcriptase toward isomers of thymidine‐5′‐O‐1‐thiotriphosphate 2005 ·Protein Science ·Jessica Radzio,Nicolas Sluis‐Cremer	7
19	Conformational Changes in HIV-1 Reverse Transcriptase Induced by Nonnucleoside Reverse Transcriptase Inhibitor Binding 2004 ·Current HIV Research ·Nicolas Sluis‐Cremer,Nuri A. Temiz,İvet Bahar	111
20	Conformational stability of Cys⁴⁵‐alkylated and hydrogen peroxide‐oxidised glutathione S‐transferase 1995 ·FEBS Letters ·Nicolas Sluis‐Cremer,Heini W. Dirr	9

About Nicolas Sluis‐Cremer

Nicolas Sluis‐Cremer is a scholar working on Virology, Infectious Diseases and Molecular Medicine, having authored 111 papers that have together received 3.1k indexed citations. Recurring topics across this work include HIV Research and Treatment (89 papers), HIV/AIDS drug development and treatment (83 papers) and HIV/AIDS Research and Interventions (37 papers). The work is most often cited by research in Virology (2.0k citations), Infectious Diseases (2.0k citations) and Molecular Medicine (330 citations). Nicolas Sluis‐Cremer has collaborated with scholars based in United States, Australia and Canada. Frequent co-authors include Gilda Tachedjian, John W. Mellors, Michael A. Parniak, Dominique Arion, Jessica Radzio, Kelly Huber, Heini W. Dirr, Yohei Doi, Jennifer M. Zerbato and Geneviève Doyon. Their work appears in journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact